The team

In addition to the position of CEO, Anna Steneholm, PhD in Respiratory Toxicology, ERT, provides support in drug development and risk assessment of chemicals, with senior expertise in EU chemical regulations (REACH & CLP) and interaction with regulatory authorities.

Stefan Czene, PhD in Oncology, provides support in risk assessment of impurities, reagents and intermediates, with long experience in genetic toxicology and (Q)SAR analysis.

Eva-Lena Glämsta, PhD in Pharmacology, ERT, provides support in drug development, with senior expertise in project management and interaction with regulatory authorities.

Hallgrimur Jonasson, PhD in Physiology, Associate professor, ERT, provides support in drug development and study outsourcing, with senior expertise in safety pharmacology.

Lizette Granberg, PhD in Environmental Toxicology, ERT, provides support in drug development and risk assessment of chemicals, with extensive experience in general toxicology.

Hanna Andersson, MSc in Pharmacy, provides support in drug development, study outsourcing and impurity/chemical risk assessment.

Axel Erbing, PhD in Chemical Physics, provides support in risk assessment of chemicals, in silico predictions, statistics, product development and regulatory compliance under REACH and CLP.

Anna Sandholm, PhD in Environmental Chemistry (focus on Metabolism, Pharmacokinetic and safety evaluation), provides support in drug development and regulatory science with senior expertise in project management and interaction with regulatory authorities.

Erik Bivehed, PhD in Genetic Toxicology, provides support in risk assessment of impurities, reagents and intermediates, with expertise in genetic toxicology, in vitro testing strategies and application of (Q)SAR modelling.

Denise Strand, PhD in Environmental Science with a focus on Toxicology, provides support in risk assessment of chemicals and regulatory compliance under CLP and REACH, with expertise in endocrine disruption and environmental contaminants.

Jan Olsson, PhD in Microbiology, ERT, provides support in drug development, with extensive experience in interactions with regulatory authorities, risk assessment and project management.